Aim: Recently, the benefit of mesenchymal stem cells (MSCs) as a cell-based therapy for acute liver failure (ALF) has gained much attention, although the mechanism of action of MSCs in the treatment of ALF remains elusive. Pyroptosis is a novel form of programmed cell death with an intense inflammatory response. The aim of the present study was to explore the soluble cytokines secreted by MSCs and their therapeutic effects through inhibiting pyroptosis in ALF.
INTRODUCTION
A CUTE LIVER FAILURE (ALF) is characterized by abrupt onset of severe liver injury, with massive hepatocyte dysfunction, and the mortality rate is as high as 90%. Liver transplantation is the most effective treatment, but its widespread clinical application is limited by the shortage of donor liver, multiple postoperative complications, and lifetime immunosuppressant treatment. 1 In recent years, the benefit of mesenchymal stem cells (MSCs) as a cell-based therapy for ALF has gained much attention. 2, 3 In addition to their differentiation ability, MSCs have the biological characteristics of low immunogenicity and immune regulation, and have shown therapeutic potential in inflammatory diseases due to their modulation of both innate and adaptive immune systems. 4 Mesenchymal stem cells can produce a variety of cytokines such as transforming growth factor-β, indoleamine 2,3-dioxygenase, inducible nitric oxide synthase, prostaglandin E2, interleukin (IL)-10, and tumor necrosis factor (TNF)-α-stimulating gene 6. 5 These properties have made MSCs a potential therapeutic choice for immune and inflammatory disorders. However, the mechanism of action of MSCs in the treatment of ALF remains elusive.
Acute liver failure destroys the balance of the liver immune microenvironment. 6 Pro-inflammatory cytokines are released, such as IL-1β, IL-6, TNF-α, chemokines, and leukotrienes. The uncontrolled immune response plays an essential role in the pathological process of ALF.
pyroptosis has an inherently pro-inflammatory nature. The activation of caspase-1 along with the inflammasome leads to the release of the pro-inflammatory cytokines (IL-1β and IL-18) and occurs before any morphologic expression of cell death. 8 Pyroptosis has been shown to play an important role in the occurrence and development of infection, nervous system diseases, and atherosclerosis. Pyroptosis is also involved in liver diseases. Hepatic endoplasmic reticulum stress can activate NLRP3 inflammasomes, leading to inflammation-mediated liver injury and hepatocyte pyroptosis. 9 Inhibition of pyroptosis is a potential therapeutic approach for the aggressive inflammatory response of acute liver diseases. Considering the anti-inflammatory effects of MSCs, we infer that they are involved in the inhibition of hepatocyte pyroptosis.
METHODS

Animals
M ALE C57BL/6 MICE aged 3-4 weeks (weight, 15-20 g) were used as MSC donors. Male C57BL/6 mice aged 6-7 weeks (weight, 25-35 g) were used as MSC recipients. All mice were purchased from the Laboratory Animal Center of the Affiliated Drum Tower Hospital of Nanjing University Medical School (Nanjing, China). This study was approved by the Institutional Animal Care and Use Committee of Nanjing University under the NIH Guide for the Care and Use of Laboratory Animals. All efforts were made to minimize suffering.
Preparation of MSCs
Mesenchymal stem cells obtained from C57BL/6 mice were isolated and cultured according to an established protocol. 10 We used flow cytometry (BD FACSAria II; BD Biosciences, San Jose, CA, USA) to identify the MSCs; the antibodies used were against mice antigens CD29, CD34, CD44, CD45, and CD90 (BD Biosciences). Positive cells were counted and compared to the signals of corresponding immunoglobulin isotypes.
Experiment design and animal groups
Acute liver failure was induced by an i.p. injection of 0.6 g/kg D-galactosamine (D-Gal). Twelve hours after ALF induction, the mice were randomly divided into six groups: (i) control ) in a volume of 0.5 mL PBS were transfused into the caudal vein over a period of 3 min. MCC950 was given i.p. to mice 1 h before the induction of liver failure. All groups of mice (n = 20 in each group) were killed 1, 2, 3, 4, 5, 6 or 7 days after treatment with D-Gal (Fig. S1 ).
Hepatocyte isolation and characterization
Primary hepatocytes were harvested by a two-step in situ collagenase perfusion technique with our modification. 12 The viability of the isolated hepatocytes determined by Trypan blue exclusion was more than 95%. Nonparenchymal cells were verified by immunocytochemical analysis of albumin and cytokeratin 18.
Establishment of co-culture system
Hepatocytes (2 × 10 5 ) were co-cultured with MSCs (2 × 10 5 ) separated by a porous membrane in 6-well culture plates for 24 h. 12 The total cell density remained constant at 1 × 10 6 cells per well. In these experiments, hepatocyte homocultures were also carried out as controls.
Cell viability assay
The cytotoxicity of the D-Gal complexes against hepatocyte homocultures and co-culture medium was assessed using the Cell Counting Kit-8 (CCK-8) (Thermo Fisher, Waltham, MA, USA) assay.
Interleukin-10 antagonist knockdown in MSCs
For shRNA-mediated RNA interference, we chose the shRNA target sequences: IL10-RNAi-Forward, 5 0 -GATC CGCTTCCAAACTGGATATAATTCAAGAGAT; and IL10-RNAi-Reverse, 5 0 -AGCTTAAAAAAGCTTCCAAACTGGAT ATAATCTCTTGAAT 0 (Ambion, Austin, TX, USA). The protein lysates extracted from the stable clone of IL-10 knocked-down MSCs and scrambled shRNA-transfected MSCs were quantified by Western blot analysis to confirm the effect of RNA interference.
Survival study
Twenty mice in each group were used for the survival study. Mice that had lived for more than 7 days after transplantation were considered to be survivors.
Enzyme-linked immunosorbent assay for inflammatory factors
To evaluate the anti-inflammatory effect of MSCs, we measured the serum concentration of the following cytokines by enzyme-linked immunosorbent assay (ELISA) (Abcam, Cambridge, UK) on day 3 after induction of ALF: IL-6, IL-1α, IL-1β, IL-10, IL-18, and TNF-α.
Measurement of hepatic enzyme and cytokine levels
The plasma levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) after treatment were measured with an automated biochemical analyzer. The levels of plasma inflammatory cytokines were detected using a commercially available ELISA kit according to the manufacturer's instruments (eBioscience, Waltham, MA, USA).
Histological and immunohistochemical study
The liver samples were fixed in 4% paraformaldehyde for 24 h before processing. Fixed liver samples were dehydrated, paraffin-embedded, and cut into small pieces (<3 mm thick, three from each liver). Sections were stained with hematoxylin-eosin (HE) for pathological assessment. All images presented in the results are representative of at least three images per liver. Images were analyzed and semiquantified using Image-Pro Plus software (Media Cybernetics, Bethesda, MD, USA).
Determination of cytokines in liver tissue using Western blot analysis
We undertook the Western blot procedure as described previously. 13 The primary antibodies were rabbit anti-caspase-1, IL-1β, and IL-18 polyclonal antibody (1:1000; Abcam); GAPDH (Abcam) expression was used as a loading control.
Statistical analysis
All data are presented as mean ± standard deviation. They were compared using ANOVA followed by Student's t-test. In the mortality study, time-to-survival data were analyzed by the Kaplan-Meier method and compared by the log-rank test. Differences between values were considered significant at P < 0.05.
RESULTS
Culture and identification of MSCs M ESENCHYMAL STEM CELLS from mouse bone marrow showed a spindle-shaped, fibroblastic morphology (Fig. 1a) . The immunophenotypic characterization by flow cytometry showed positive stromal marker expression (CD29, CD44, and CD90), but little or no hematopoietic marker expression (CD34 and CD45), which means a high purity after the third passage (Fig. 1b) .
Mesenchymal stem cells ameliorate liver injury in ALF
Mesenchymal stem cells were injected i.v. 12 h after D-Gal injection to determine the therapeutic efficacy of MSCs in ALF. The engraftment of MSCs retained in the liver was approximately 0.5% (Fig. S2 ). In the D-Gal-treated group, 70% of mice did not survive for 3 days. By contrast, in the MSC-treated group, 60% of mice survived >7 days after ALF induction (Fig. 2a) . As expected, in the MSC-treated group, there was a significant decrease in ALT and AST levels at each time point (P < 0.05), while the injection of saline showed no difference (Fig. 2b) . All of them reached a peak on day 3. Staining with HE was carried out to investigate the liver histology of mice with ALF after transplantation of MSCs. The ALF group showed extensive large nodules, severe infiltration of lymphocytes, hepatic cell necrosis and hemorrhaging involving entire lobules, and the hepatocytes had swollen cytoplasm. However, MSC transplantation improved the histological damage (Fig. 2c) . It seems that i.v. injection of MSCs could attenuate liver injury.
Mesenchymal stem cells regulate inflammatory cytokines
To investigate the change in the inflammatory microenvironment, we detected the liver levels of inflammatory factors (interferon (IFN)-γ, IL-6, IL-1α, IL-1β, IL-10, IL-18, and TNF-α) by ELISA on day 3 after injection of MSCs. Pro-inflammatory molecules such as IFN-γ, IL-1β, and IL-18 showed a significant reduction after administration of MSCs, whereas anti-inflammatory cytokine IL-10 showed higher expression. These data indicate that MSCs play an anti-inflammatory role in secretion of anti-inflammatory cytokines (Fig. 2d) .
Hepatocyte pyroptosis exacerbates ALF through production of NLRP3-caspase-1 inflammasomes
Interleukin-1β and IL-18 acted as pro-inflammatory factors and were markedly increased in acute liver injury. They have been reported as significant cytokines in the process of pyroptosis. 8 We treated mice i.p. with 50 mg/kg MCC950 or vehicle control (PBS) 1 h before i.p. injection of D-Gal.
14 Inhibition of NLRP3 also increased the survival rate significantly (Fig. 3a) . Both ALT and AST decreased significantly and hepatic inflammation was resolved, in contrast to ALF mice (Fig.3b,c) . MCC950 treatment also decreased the concentration of IL-18 and IL-1β in liver ( Fig.3d) . These data clearly indicate that MCC950 effectively and specifically blocks NLRP3 activation in vivo.
When hepatocytes from a normal mouse were stimulated with D-Gal, NLRP3, caspase-1, and IL-1β processing was detected in the cell supernatants. However, when treated with 1 μM MCC950 12 h 14 before D-Gal, NLRP3, IL-1β, and caspase-1 processing was dose-dependently inhibited (Fig. 4a) . The CCK8 assay indicated that cell viability in the MCC950-treated group was increased significantly (Fig. 4b) . Thus, NLRP3-caspase-1 inflammasomes accelerate hepatocyte death through pyroptosis. The NLRP3-caspase-1 inflammasome activation stimulated liver injury, thus, inhibition of hepatocyte pyroptosis may play a role in liver repair.
Mesenchymal stem cells attenuate ALF through inhibition of hepatocyte pyroptosis
The NLRP3-caspase-1 inflammasomes were markedly reduced when hepatocytes were co-cultured with MSCs (Fig. 4c) . These results suggested that MSCs can attenuate pyroptosis in D-Gal treated hepatocytes. To investigate pyroptosis in ALF and whether MSCs reverse injury through inhibition of pyroptosis, we examined the levels of NLRP3, IL-1β, IL-18, and caspase-1 in the liver on day 3. Consistently, the D-Gal-treated group showed high levels of all of these markers, whereas the MSC-treated group showed dramatically decreased (Fig. 4d) . These results indicate that MSCs can reduce liver injury through inhibition of hepatocyte pyroptosis.
Mesenchymal stem cells decrease ALF-related injury through induction of IL-10
The data in our previous study on an ALF model 13 showed that IL-10 released by MSCs has therapeutic potential in ALF. To block IL-10 secretion from MSCs in this study, we used ShIL-10 RNA to infect MSCs (Fig. 5a ). Mice with ALF were treated i.v. in four different groups to detect therapeutic efficacy of IL-10 derived from MSCs: ALF, MSCs, ShIL-10 MSCs, and IL-10 groups. Three days later, neither ALT nor AST showed significant improvement after treatment with ShIL-10 MSCs. However, treatment with IL-10 resulted in a significant decrease in ALT and AST levels compared with the MSC-treated group (Fig. 5b) . Hematoxylin-eosin staining and survival rates showed similar results (Fig. 5c,d ). This indicates that MSCs can release IL-10, which plays an important role in reducing ALF.
Mesenchymal stem cells inhibit hepatocyte pyroptosis through induction of IL-10
As mentioned above, MSCs relieved liver injury through pyroptosis inhibition. As IL-10 is the most important anti-inflammatory cytokine released from MSCs, the efficacy of IL-10 in hepatocyte pyroptosis needs to be determined. In vitro, D-Gal-treated hepatocyte medium within 0.02 μg/mL IL-10 had little caspase-1 activation and secreted low levels of NLRP3, IL-1β, and IL-18 in contrast with D-Gal-treated hepatocyte medium (Fig. 5e) . Interleukin-10 decreased the production of proinflammatory cytokines. In vivo, we treated four groups of ALF mice with PBS, MSCs, ShIL-10 MSCs, and IL-10. The levels of NLRP3, IL-1β, IL-18, and caspase-1 activation in the ShIL-10 group showed no significant change (P > 0.05) compared with the PBS group, whereas MSCs decreased the levels markedly (P < 0.05), and levels in the IL-10 group were slightly higher than in the MSC group (Fig. 5f ). Consistent with our expectations, mortality rate, liver function indexes (ALT and AST), and inflammation (HE staining) increased again after administration of ShIL-10 MSCs (Fig. 5b-d) . These data indicated that MSCs inhibit hepatocyte pyroptosis to mediate their therapeutic effect in ALF by releasing anti-inflammatory cytokine IL-10.
DISCUSSION
A CUTE LIVER FAILURE is a critical disease with rapid dysfunction of hepatocytes accompanied by uncontrollable systemic inflammation. After the establishment of the D-Gal-induced ALF model, 70% of mice did not survive after 3 days. We found a sharp increase in ALT and AST. The expressions of pro-inflammatory cytokines (IFN-γ, IL-6, IL-1β, IL-18, and TNF-α) were significantly enhanced while anti-inflammatory cytokines (IL-1α and IL-10) decreased dramatically. Our results suggest that ALF is a state of robust cellular immune response. Immune microenvironment changes are consistent with clinical symptoms, which suggests a role for the immune microenvironment in the process of ALF.
Mesenchymal stem cells have been studied for their therapeutic effect in ALF for several years. The mechanism remains controversial. It has been reported that stem cells facilitate liver repair by transdifferentiation into primary hepatocytes. 15, 16 However, this possibility has been challenged in other studies. Puppi et al. reported that only a small number of donor-derived cells were detected in vivo, which was not enough to replace the damaged hepatocytes. 17 Recently, immunoregulation by cytokine secretion has been supported as a novel mechanism of MSC transplantation. These released factors play an important role in attenuating systemic inflammation, inhibiting apoptosis, and repairing tissue. [18] [19] [20] In both our previous and current studies, 13 we found that MSCs significantly improved liver function (including ALT and AST) as well as the survival rate in D-Gal-induced ALF. We also showed that MSC-derived IL-10 was the most distinct among the anti-inflammatory cytokines, suggesting a crucial role in the treatment of ALF with MSCs. Consistently, improvement of the inflammatory environment was abolished after inhibition of IL-10 by ShRNA. Interleukin-10 reduced the expression of pro-inflammatory cytokines and played an important role in reducing the inflammatory response. Therefore, MSC treatment could improve ALF by maintaining longer and higher IL-10 expression than endogenous induction by D-Gal.
Pyroptosis was originally described as caspase-1-dependent cell death; it can occur in vitro 21 and in vivo. 22 Recently, the inherently pro-inflammatory nature of pyroptosis has been recognized. An inflammasome is a cytosolic, multiprotein platform that enables the activation of pro-inflammatory caspases, chiefly caspase-1, through the induction of caspase-1 cleavage and release of IL-1β, IL-18, and other pro-inflammatory cytokines, which eventually produce inflammation. 23 Three types of inflammasomes are known. Both NLRC4 and NLRP1 contain CARD domains that directly interact with the caspase-1 CARD. 24 NLRP3 contains a Pyrin signaling domain that binds the Pyrin domain of the adaptor protein ASC, which recruits caspase-1 through CARD- CARD interactions. 25 AIM2 contains a HIN200 domain and a Pyrin domain that recruits ASC and activates caspase-1. 26 Each of these inflammasomes can activate caspase-1 to trigger pyroptosis. 27 As expected, NLRP3 blockage markedly alleviates hepatic dysfunction in DGal-treated mice. To confirm the role of pyroptosis progress in acute hepatocyte damage, we cultured mouse hepatocytes stimulated with MCC950 and D-Gal. The NLRP3 deficiency resulted in less death in response to DGal exposure. The levels of pro-inflammatory IL-1β, IL-18, and caspase-1 decreased markedly. It seems that NLRP3 stimulates the occurrence of pyroptosis while its inhibition can ameliorate liver inflammation and injury.
Acute liver failure leads to a large number of antigens, a series of immune cells, inflammatory factors, and chemokines in a high-stress state. Imbalance of the liver immune microenvironment can result in a lot of excessively activated immune cells that effect feedback immune damage to liver. Pyroptosis is often associated with a high inflammatory state, in contrast to the silent apoptotic death, and frequently occurs following infection. 28 The NLRP3-caspase-1 inflammasome is a key inflammatory mediator driving the host response to infection, 29 injury, 30 and disease. 21, 31 In our work, MSCs repaired ALF through IL-10 production, while inflammasomes aggravate liver injury. To determine whether MSCs alleviate pyroptosis to cure liver dysfunction through the same mechanism, we used ShIL-10 RNA to inhibit MSC secretion. We found that IL-10 has the capacity to inhibit expression of NLRP3. Interleukin-10 negatively regulates the expression of NLRP3 inflammasome components and provides a link to degenerative liver function.
The current study was preliminary and included in vivo and in vitro studies. In the near future, we will carry out further preclinical studies to validate the present findings. It is necessary to establish the whole network of IL-10-induced anti-inflammatory factors, which may help to discover novel biomarkers for predicting the efficacy of MSCs in ALF.
In conclusion, MSCs can release anti-inflammatory factor IL-10, which can reduce the levels of NLRP3-caspase-1 inflammasomes and play an important role in anti-pyroptosis in the treatment of ALF.
